Moderna Share Forecast January 2022 – Time to Buy MRNA?
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only.
Shares of Moderna closed at $204.73 as of January 14th (19:59 EST). Demand for Moderna’s vaccine is expected to fall in the coming years. But the company’s current valuation will only be sustainable if the demand remains steady.
To appear attractive to investors, Moderna needs to get down to a market cap of $60 billion. The shares are currently far below their peak market cap last summer of $200 million.
Moderna – Technical Analysis
According to the financial statement, Moderna’s market cap is at $83.008 billion with total assets worth $20.923 billion. Revenue for 2020 was at $803.39 million with a profit margin of -92.99% compared to $0.21 million in 2019.
Oscillators such as Relative Strength Index (14)(34.30), Stochastic %K (14, 3, 3)(16.58), Commodity Channel Index (20)(−122.95), Average Directional Index (14)(17.84) and Awesome Oscillator(−43.12)are neutral. Moving averages such as Exponential Moving Average (10)(222.43), Simple Moving Average (10)(220.61), Exponential Moving Average (20(236.17), Simple Moving Average (20)(239.43) and Exponential Moving Average (30)(247.04) are indicating a sell action.
68% of all retail investor accounts lose money when trading CFDs with this provider.
Recent Developments
Moderna partnered with Lonza Group to produce almost 1 billion doses in 2021. The company began Phase I clinical trials began for mRNA-1283, on June 25th 2021, which is meant to be a vaccine booster. Moderna’s covid vaccine was approved by the United Kingdom’s Medicines and Healthcare products Regulatory Agency for application on Children aged 12 to 17.
Moderna has been serving us with its vaccines for most of the pandemic. Along with vaccine maker Pfizer, both the companies have now said that boosters or vaccines will have to be renewed annually. Due to the Omicron variant, Moderna has secured advance purchase agreements from various countries through 2024.
For instance, Switzerland and South Korea signed on additional booster doses to be delivered this year.
Moderna is also well on its way to preparing a combined coronavirus-flu vaccine. The new drug is in the preclinical stage right now and reduces the number of shots needed for protection against two viruses.
While commercialising such a vaccine will take time, Moderns is working on developing strain-specific booster candidates.
While some target micron, others are aiming at a range of emerging variants. These drugs are in various stages of development from pre-clinical to phase 2.
Investors must also remember that Moderns isn’t just a coronavirus vaccine company and has 37 programs in the pipeline in a variety of areas. These include working on an HIV vaccine, cancer vaccines, and an inhaled pulmonary therapeutic for cystic fibrosis among others.
It recently launched a phase 3 pivotal trial of its cytomegalovirus (CMV) vaccine candidate. Such a vaccine for CMV doesn’t exist, which will provide Moderna with the opportunity to seize the first-to-market advantage.
Should You Buy MRNA Shares?
The above developments indicate that Moderna’s vaccine revenue won’t sink anytime soon. Management has predicted 2021 vaccine revenue of $15 billion to $18 billion. Moderna has also maintained the same level of advanced purchase agreements as last year.
The whole world right now is focusing on which vaccines deal with the variants most effectively. As newer variants regularly start to emerge, Moderna is in a good position.
The company can solidify its vaccine leadership by tackling new strains that emerge. Right now MRNS shares are trading for only seven times forward earnings estimates. Considering this, the shares are a bargain considering the company’s near-term and long-term prospects. Moderns is a great buy today eventhough shares have skyrocketed.
Buy MRNA Stock at eToro from just $50 Now!
